Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
JANX Stock Chart & Stats
$13.80
-$2.71(-4.69%)
At close: 4:00 PM EST
$13.80
-$2.71(-4.69%)
Day’s Range― - ―
52-Week Range$12.80 - $45.79
Previous CloseN/A
Volume1.13M
Average Volume (3M)1.50M
Market Cap
$841.47M
Enterprise Value$776.04M
Total Cash (Recent Filing)$988.99M
Total Debt (Recent Filing)$22.66M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Mar 06, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding60,147,808
10 Day Avg. Volume1,846,255
30 Day Avg. Volume1,504,356
Financial Highlights & Ratios
PEG Ratio13.76
Price to Book (P/B)2.81
Price to Sales (P/S)271.80
P/FCF Ratio-65.15
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue77.60
Enterprise Value/Gross Profit81.70
Enterprise Value/Ebitda-5.91
Forecast
1Y Price Target
$52.58Price Target Upside281.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Safety ProfileUpdated clinical data indicate a favorable safety profile for the lead asset, with no serious adverse events or dose-limiting toxicities reported and a mitigation protocol reducing severe immune reactions.
Indication Expansion And Market OpportunityInitiation of expansion cohorts that test the prostate cancer candidate in earlier-line patients expands the addressable population and could materially increase commercial potential if efficacy is sustained.
Partnerships And LicensingAn exclusive collaboration and license agreement with a major pharmaceutical company validates the tumor-activated platform and brings external resources for later-stage development and global commercialization.
Bears Say
Competitive Differentiation And EfficacyRecent efficacy results that align with an existing approved therapy reduce differentiation versus competitors and could constrain market share in a crowded treatment setting.
Dose Selection And Pivotal Trial RiskUncertainty around the final Phase 2 dose and dosing schedule creates risk for pivotal trial design and regulatory timing, which could delay development plans.
Safety Concerns — CardiotoxicityA reported fatal heart-related adverse event linked to the program raises serious cardiovascular safety concerns and may prompt additional monitoring or regulatory scrutiny.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $12.80 and its highest was $45.79 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Janux Therapeutics Inc’s market cap is $841.47M.
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is Mar 06, 2026 which is in 29 days.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.612 by $0.222.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -0.62.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 60,147,808 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.612. Following the earnings report the stock price went down -7.606%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.58 (281.01% Upside)
$52.58 (281.01% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 275.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $173.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.1%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.19%
12-Months-Change
Fundamentals
Return on Equity
-12.48%
Trailing 12-Months
Asset Growth
47.44%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$52.58
▲(281.01% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
Currently, No data available
---